

Supplemental Table 1

Anti-Ad-5 Neutralizing Antibody Titer	Pre	Post 1 Vaccine	Post 2 Vaccines	Post 3 Vaccines	Post 4 or 5 Vaccines
Positive at $\geq 1:100$ serum dilution	3/18 (17%)	4/5 (80%)	17/17 (100%)	15/15 (100%)	5/5 (100%)
Positive at $\geq 1:500$ serum dilution	3/18 (17%)	1/5 (20%)	14/17 (82%)	15/15 (100%)	5/5 (100%)
Positive at $\geq 1:1,000$ serum dilution	1/18 (6%)	1/5 (20%)	9/17 (53%)	8/15 (53%)	5/5 (100%)
Positive at $\geq 1:5,000$ serum dilution	0/18 (0%)	1/5 (20%)	5/17 (29%)	6/15 (40%)	3/5 (60%)
Positive at $\geq 1:10,000$ serum dilution	0/18 (0%)	1/5 (20%)	3/17 (18%)	2/15 (13%)	2/5 (40%)


Supplemental Table 1: Frequency of patients with anti-Ad5 Neutralizing Antibodies Pre and post vaccination.

Supplemental Table 2

Serum Soluble Factor and Cytokines	Patients with PSA Decline		Patient without PSA Decline	
	Increase >10%	Decrease >10%	Increase >10%	Decrease >10%
sCD40L	1/5 (20%)	4/5 (80%)	6/13 (46%)	1/13 (8%)
IL-8	5/5 (100%)	0/5 (0%)	5/13 (38%)	8/13 (62%)

Supplemental Table 2: Frequency of patients with a >10% change (increase or decrease) in soluble CD40L (sCD40L) or interleukin-8 (IL-8) at 3 or 6 weeks post vaccination.

Supplemental Figure 1



Supplemental Figure 1: Level of Serum Analytes. **A, B.** Levels of interleukin-8 (IL-8) and soluble PD-1 (sPD1) were statistically significantly elevated at baseline in cancer patients enrolled on this study compared to healthy donors (HD). **C, D.** Levels of soluble CD27 (sCD27) and sPD1 were significantly increased at 42 days (post 2 vaccinations) compared to pre (day 1).